3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
73
Squamous Cell Carcinoma of Head and Neck
40
Lung Neoplasms
36
Oropharyngeal Neoplasms
21
Urinary Bladder Neoplasms
20
Nasopharyngeal Carcinoma
19
Head and Neck Neoplasms
19
Carcinoma
15
Small Cell Lung Carcinoma
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Esophageal Squamous Cell Carcinoma
13
Cholangiocarcinoma
13
Biliary Tract Neoplasms
13
Neoplasms
12
Neoplasm Metastasis
12
Uterine Cervical Neoplasms
11
Ovarian Neoplasms
11
Colorectal Neoplasms
11
Laryngeal Neoplasms
10
Carcinoma, Squamous Cell
10
Stomach Neoplasms
9
Gallbladder Neoplasms
9
Carcinoma, Transitional Cell
9
Pancreatic Neoplasms
8
Mouth Neoplasms
8
Hypopharyngeal Neoplasms
7
Esophageal Neoplasms
7
Bile Duct Neoplasms
7
Mesothelioma, Malignant
6
Endometrial Neoplasms
6
Interventions
pembrolizumab
1
Pemetrexed
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Cisplatin
×
90 days
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled